Abstract 13750: Cardiac Resynchronization Therapy for Patients With Cardiac Sarcoidosis
Objective: Little is known about the clinical features in patients with cardiac sarcoidosis who receive cardiac resynchronization therapy (CRT). We aimed to clarify the clinical response to CRT in patients with cardiac sarcoidosis.
Methods: We compared the clinical data on CRT between heart failure patients with cardiac sarcoidosis and those with other etiologies at 3 cardiovascular centers. The primary endpoint was composite outcome of cardiovascular death or hospitalization from worsening heart failure within 5 years after the CRT.
Results: The patients with cardiac sarcoidosis (N=18) were more likely than those without cardiac sarcoidosis (N=141) to be female (83.3% vs. 22.7%; P<0.001), and undergo an upgrade from a pacemaker or implantable cardioverter defibrillator (72.2% vs. 18.4%; P<0.001). The composite outcome occurred with a similar frequency (38.9% vs. 48.2%; P=0.37). The patients with cardiac sarcoidosis were more likely than those without to have sustained ventricular arrhythmias occurring before or after the CRT (66.7% vs. 29.1%; P=0.003). The reduction in the left ventricular end-systolic volume after the CRT was significantly smaller in the patients with cardiac sarcoidosis than in those without (mean±SD, -1.5±28.7 vs. -20.1±33.7%; P=0.03). Patients with an improved clinical composite score were seen with a similar proportion (55.6% vs. 61.7%; P=0.86).
Conclusions: Outcomes after the CRT may be acceptable in patients with cardiac sarcoidosis. A poor left ventricular reverse remodeling and higher occurrence of ventricular arrhythmias may characterize them.
Author Disclosures: A. Sairaku: None. Y. Yoshida: None. Y. Nakano: None. M. Maeda: None. H. Hashimoto: None. H. Hirayama: None. Y. Kihara: None.
- © 2015 by American Heart Association, Inc.